seres therapeutics inc. - MCRB
MCRB
Close Chg Chg %
8.94 -0.44 -4.92%
Closed Market
8.50
-0.44 (4.92%)
Volume: 25.52K
Last Updated:
Apr 21, 2026, 4:00 PM EDT
Company Overview: seres therapeutics inc. - MCRB
MCRB Key Data
| Open $8.81 | Day Range 8.50 - 9.11 |
| 52 Week Range 6.54 - 29.98 | Market Cap $85.70M |
| Shares Outstanding 9.59M | Public Float 7.24M |
| Beta 0.26 | Rev. Per Employee N/A |
| P/E Ratio 13.92 | EPS $0.82 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 43.65K |
MCRB Performance
| 1 Week | -4.39% | ||
| 1 Month | 0.00% | ||
| 3 Months | -43.52% | ||
| 1 Year | -15.67% | ||
| 5 Years | -97.92% |
MCRB Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
1
Full Ratings ➔
About seres therapeutics inc. - MCRB
Seres Therapeutics, Inc. engages in the development of biological drugs through microbiome therapeutics platform. Its product pipeline includes SER-109, SER-287, SER-301, and SER-401. The company was founded by Geoffrey von Maltzahn, David A. Berry, and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.
MCRB At a Glance
Seres Therapeutics, Inc.
101 Cambridge Park Drive
Cambridge, Massachusetts 02140
| Phone | 1-617-945-9626 | Revenue | 789.00K | |
| Industry | Biotechnology | Net Income | 5.70M | |
| Sector | Health Technology | Employees | 66 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
MCRB Valuation
| P/E Current | 13.921 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 23.17 |
| Price to Sales Ratio | 167.277 |
| Price to Book Ratio | 3.216 |
| Price to Cash Flow Ratio | 118.16 |
| Enterprise Value to EBITDA | -1.883 |
| Enterprise Value to Sales | 214.426 |
| Total Debt to Enterprise Value | 0.49 |
MCRB Efficiency
| Revenue/Employee | 11,954.545 |
| Income Per Employee | 86,303.03 |
| Receivables Turnover | 1.526 |
| Total Asset Turnover | 0.006 |
MCRB Liquidity
| Current Ratio | 2.555 |
| Quick Ratio | 2.555 |
| Cash Ratio | 2.369 |
MCRB Profitability
| Gross Margin | -423.828 |
| Operating Margin | -11,910.139 |
| Pretax Margin | 721.926 |
| Net Margin | 721.926 |
| Return on Assets | 4.098 |
| Return on Equity | 19.641 |
| Return on Total Capital | 4.479 |
| Return on Invested Capital | 5.335 |
MCRB Capital Structure
| Total Debt to Total Equity | 187.629 |
| Total Debt to Total Capital | 65.233 |
| Total Debt to Total Assets | 60.036 |
| Long-Term Debt to Equity | 164.132 |
| Long-Term Debt to Total Capital | 57.064 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Seres Therapeutics Inc. - MCRB
Collapse All in section
| All values USD millions. | 2022 | 2023 | 2024 | 2025 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| - | 7.13M | 126.33M | 789.00K | |
Sales Growth
| - | -95.08% | +1,672.24% | -100.00% | |
Cost of Goods Sold (COGS) incl D&A
| 11.85M | 15.11M | 14.70M | 4.13M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 11.85M | 15.11M | 14.70M | 4.13M | |
Depreciation
| 11.85M | 15.11M | 14.70M | 4.13M | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| - | +27.51% | -2.75% | -71.88% | |
Gross Income
| (4.72M) | 111.21M | (14.70M) | (3.34M) | |
Gross Income Growth
| - | +2,453.67% | -113.22% | +77.25% | |
Gross Profit Margin
| - | -66.29% | +88.04% | -423.83% |
| 2022 | 2023 | 2024 | 2025 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 240.76M | 218.49M | 103.35M | 90.63M | |
Research & Development
| 172.92M | 145.86M | 61.87M | 49.06M | |
Other SG&A
| 67.84M | 72.63M | 41.48M | 41.57M | |
SGA Growth
| +19.23% | -9.25% | -52.70% | -12.31% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | 3.27M | - |
EBIT after Unusual Expense
| (245.49M) | (107.28M) | (121.31M) | (93.97M) | |
Non Operating Income/Expense
| 1.35M | 6.73M | (4.46M) | 99.67M | |
Non-Operating Interest Income
| 3.06M | 7.30M | 3.97M | 2.23M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | 6.02M | 13.18M | - |
Interest Expense Growth
| - | - | +106.87% | +118.87% | - |
Gross Interest Expense
| - | - | 6.02M | 13.18M | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (250.16M) | (113.72M) | (125.77M) | 5.70M | |
Pretax Income Growth
| -281.46% | +54.54% | -10.59% | +104.53% | |
Pretax Margin
| - | -3,509.50% | -90.02% | +721.93% | |
Income Tax
| - | - | - | - | - |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (250.16M) | (113.72M) | (125.77M) | 5.70M | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (250.16M) | (113.72M) | (125.77M) | 5.70M | |
Net Income Growth
| -281.46% | +54.54% | -10.59% | +104.53% | |
Net Margin Growth
| - | -3,509.50% | -90.02% | +721.93% | |
Extraordinaries & Discontinued Operations
| - | - | - | (20.80M) | - |
Discontinued Operations
| - | - | - | (20.80M) | - |
Net Income After Extraordinaries
| (250.16M) | (113.72M) | (146.57M) | 5.70M | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (250.16M) | (113.72M) | (146.57M) | 5.70M | |
EPS (Basic)
| -46.2924 | -17.769 | -18.8636 | 0.643 | |
EPS (Basic) Growth
| -223.67% | +61.62% | -6.16% | +103.41% | |
Basic Shares Outstanding
| 5.40M | 6.40M | 7.77M | 8.86M | |
EPS (Diluted)
| -46.2924 | -17.769 | -18.8636 | 0.6422 | |
EPS (Diluted) Growth
| -223.67% | +61.62% | -6.16% | +103.40% | |
Diluted Shares Outstanding
| 5.40M | 6.40M | 7.77M | 8.87M | |
EBITDA
| (233.63M) | (92.17M) | (103.35M) | (89.84M) | |
EBITDA Growth
| -309.86% | +60.55% | -12.14% | +13.07% | |
EBITDA Margin
| - | -3,277.68% | -72.96% | -11,386.31% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 21.00 | |
| Number of Ratings | 1 | Current Quarters Estimate | -2.11 | |
| FY Report Date | 06 / 2026 | Current Year's Estimate | -8.23 | |
| Last Quarter’s Earnings | -1.88 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 0.64 | Next Fiscal Year Estimate | -9.17 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 1 | 1 | 1 | 1 |
| Mean Estimate | -2.11 | -2.17 | -8.23 | -9.17 |
| High Estimates | -2.11 | -2.17 | -8.23 | -9.17 |
| Low Estimate | -2.11 | -2.17 | -8.23 | -9.17 |
| Coefficient of Variance | N/A | N/A | N/A | N/A |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 1 | 1 | 1 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 0 | 0 | 2 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Overweight |
SEC Filings for Seres Therapeutics Inc. - MCRB
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Seres Therapeutics Inc. - MCRB
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| May 20, 2025 | Matthew R. Henn See Remarks | 4,362 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 20, 2025 | Teresa L. Young See Remarks | 1,073 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 20, 2025 | Teresa L. Young See Remarks | 929 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 20, 2025 | Teresa L. Young See Remarks | 5,044 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $7.28 per share | 36,720.32 |
| May 20, 2025 | Teresa L. Young See Remarks | 5,107 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 20, 2025 | Teresa L. Young See Remarks | 5,009 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 20, 2025 | Matthew R. Henn See Remarks | 1,073 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 20, 2025 | Matthew R. Henn See Remarks | 985 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 20, 2025 | Matthew R. Henn See Remarks | 4,383 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $7.28 per share | 31,908.24 |
| May 20, 2025 | Matthew R. Henn See Remarks | 4,460 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 20, 2025 | Thomas J. DesRosier Chief Legal Officer and EVP | 7,255 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 20, 2025 | Eric D. Shaff CEO and President; Director | 3,653 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 20, 2025 | Eric D. Shaff CEO and President; Director | 2,735 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 20, 2025 | Eric D. Shaff CEO and President; Director | 10,102 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $7.28 per share | 73,542.56 |
| May 20, 2025 | Eric D. Shaff CEO and President; Director | 10,322 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 20, 2025 | Eric D. Shaff CEO and President; Director | 9,991 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 20, 2025 | Thomas J. DesRosier Chief Legal Officer and EVP | 1,224 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 20, 2025 | Thomas J. DesRosier Chief Legal Officer and EVP | 929 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 20, 2025 | Thomas J. DesRosier Chief Legal Officer and EVP | 7,287 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $7.28 per share | 53,049.36 |
| May 20, 2025 | Thomas J. DesRosier Chief Legal Officer and EVP | 7,366 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |